CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Lisata Therapeutics, Inc - LSTA CFD

2.44
5.43%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.18
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 2.58
Open* 2.51
1-Year Change* -19.81%
Day's Range* 2.38 - 2.62
52 wk Range 0.40-1.26
Average Volume (10 days) 131.69K
Average Volume (3 months) 2.95M
Market Cap 30.92M
P/E Ratio -100.00K
Shares Outstanding 60.58M
Revenue N/A
EPS -0.41
Dividend (Yield %) N/A
Beta 0.91
Next Earnings Date Nov 2, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 7, 2023 2.58 0.49 23.44% 2.09 2.69 2.09
Dec 6, 2023 2.44 0.29 13.49% 2.15 2.57 2.09
Dec 5, 2023 2.19 -0.07 -3.10% 2.26 2.29 2.11
Dec 4, 2023 2.25 0.14 6.64% 2.11 2.25 2.07
Dec 1, 2023 2.14 0.06 2.88% 2.08 2.14 2.08
Nov 30, 2023 2.17 -0.17 -7.26% 2.34 2.38 2.06
Nov 29, 2023 2.43 0.04 1.67% 2.39 2.43 2.22
Nov 28, 2023 2.39 0.06 2.58% 2.33 2.41 2.24
Nov 27, 2023 2.41 -0.03 -1.23% 2.44 2.48 2.39
Nov 24, 2023 2.29 0.05 2.23% 2.24 2.43 2.24
Nov 22, 2023 2.24 0.15 7.18% 2.09 2.24 2.04
Nov 21, 2023 2.16 0.07 3.35% 2.09 2.21 2.09
Nov 20, 2023 2.19 0.00 0.00% 2.19 2.20 2.09
Nov 17, 2023 2.23 0.03 1.36% 2.20 2.26 2.19
Nov 16, 2023 2.24 0.05 2.28% 2.19 2.25 2.19
Nov 15, 2023 2.23 0.01 0.45% 2.22 2.24 2.14
Nov 14, 2023 2.22 0.13 6.22% 2.09 2.24 2.09
Nov 13, 2023 2.12 0.03 1.44% 2.09 2.13 2.09
Nov 10, 2023 2.13 0.00 0.00% 2.13 2.20 2.06
Nov 9, 2023 2.09 -0.08 -3.69% 2.17 2.22 2.02

Lisata Therapeutics, Inc Events

Time (UTC) Country Event
Thursday, March 28, 2024

Time (UTC)

20:00

Country

US

Event

Q4 2023 Lisata Therapeutics Inc Earnings Release
Q4 2023 Lisata Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 0 0 0 0 0
Total Operating Expense 29.05 19.145 20.092 16.987 27.593
Selling/General/Admin. Expenses, Total 11.37 9.892 9.295 9.393 11.7501
Research & Development 17.68 9.253 10.797 7.594 15.843
Operating Income -29.05 -19.145 -20.092 -16.987 -27.593
Interest Income (Expense), Net Non-Operating 0.151 0 -0.005 -0.37777
Other, Net -0.075 0.132 0.74 0.824 0.2731
Net Income Before Taxes -28.974 -19.013 -19.352 -16.168 -27.6977
Net Income After Taxes -27.466 -8.141 -19.352 -16.168 -16.1712
Minority Interest 0 -0.009 -0.009 0.001 0.18246
Net Income Before Extra. Items -27.466 -8.15 -19.361 -16.167 -15.9887
Total Extraordinary Items 0 38.9674
Net Income -27.466 -8.15 -19.361 -16.167 22.9787
Income Available to Common Excl. Extra. Items -27.466 -8.15 -19.361 -16.167 -15.9887
Income Available to Common Incl. Extra. Items -27.466 -8.15 -19.361 -16.167 22.9787
Diluted Net Income -27.466 -8.15 -19.361 -16.167 22.9787
Diluted Weighted Average Shares 55.313 15.44 10.325 9.689 8.96895
Diluted EPS Excluding Extraordinary Items -0.49656 -0.52785 -1.87516 -1.66859 -1.78267
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.49656 -0.52785 -1.87516 -1.66859 -1.78267
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 0 0 0 0 0
Total Operating Expense 6.62 6.849 6.968 7.147 8.086
Selling/General/Admin. Expenses, Total 3.342 2.699 2.843 2.818 3.01
Research & Development 3.278 4.15 4.125 4.329 5.076
Operating Income -6.62 -6.849 -6.968 -7.147 -8.086
Interest Income (Expense), Net Non-Operating 0.063 0.04 0.041 0.047 0.023
Net Income Before Taxes -6.705 -6.794 -6.927 -7.19 -8.063
Net Income After Taxes -4.226 -6.794 -6.927 -5.682 -8.063
Minority Interest 0 0 0 0 0
Net Income Before Extra. Items -4.226 -6.794 -6.927 -5.682 -8.063
Net Income -4.226 -6.794 -6.927 -5.682 -8.063
Income Available to Common Excl. Extra. Items -4.226 -6.794 -6.927 -5.682 -8.063
Income Available to Common Incl. Extra. Items -4.226 -6.794 -6.927 -5.682 -8.063
Diluted Net Income -4.226 -6.794 -6.927 -5.682 -8.063
Diluted Weighted Average Shares 60.56 59.819 59.614 59.51 42.117
Diluted EPS Excluding Extraordinary Items -0.06978 -0.11358 -0.1162 -0.09548 -0.19144
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS -0.06978 -0.11358 -0.1162 -0.09548 -0.19144
Other, Net -0.148 0.015 0 -0.09
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 96.182 35.331 25.972 44.106 61.397
Cash and Short Term Investments 94.97 34.573 25.157 43.053 55.08
Cash & Equivalents 24.647 16.512 14.032 10.299 29.163
Short Term Investments 70.323 18.061 11.125 32.754 25.917
Total Receivables, Net
Accounts Receivable - Trade, Net
Prepaid Expenses 1.212 0.758 0.815 1.053 1.312
Other Current Assets, Total 0 5.005
Total Assets 97.008 36.002 27.153 44.58 63.376
Property/Plant/Equipment, Total - Net 0.786 0.631 1.006 0.165 0.257
Other Long Term Assets, Total 0.04 0.04 0.175 0.309 1.722
Total Current Liabilities 4.523 3.506 5.976 5.619 9.314
Accounts Payable 1.934 1.02 1.49 0.762 1.343
Accrued Expenses 2.589 2.486 4.486 4.857 7.812
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0.159
Other Current Liabilities, Total
Total Liabilities 4.754 3.506 6.337 6.854 12.869
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Minority Interest -0.254 -0.254 -0.263 -0.272 -0.318
Other Liabilities, Total 0.485 0.254 0.624 1.507 3.873
Total Equity 92.254 32.496 20.816 37.726 50.507
Common Stock 0.06 0.019 0.011 0.01 0.009
Additional Paid-In Capital 545.988 458.748 438.911 436.433 433.044
Retained Earnings (Accumulated Deficit) -453.016 -425.55 -417.4 -397.977 -381.81
Treasury Stock - Common -0.708 -0.708 -0.708 -0.708 -0.708
Other Equity, Total -0.07 -0.013 0.002 -0.032 -0.028
Total Liabilities & Shareholders’ Equity 97.008 36.002 27.153 44.58 63.376
Total Common Shares Outstanding 59.7897 19.3783 10.5176 9.85466 9.47283
Total Preferred Shares Outstanding 0.01 0.01 0.01 0.01 0.01
Property/Plant/Equipment, Total - Gross 1.154 0.944 1.255
Accumulated Depreciation, Total -0.368 -0.313 -0.249
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 90.7 96.182 102.107 108.08 114.033
Cash and Short Term Investments 88.519 94.97 100.149 106.09 111.511
Cash & Equivalents 12.747 24.647 12.772 12.935 28.744
Short Term Investments 75.772 70.323 87.377 93.155 82.767
Prepaid Expenses 2.181 1.212 1.958 1.99 2.522
Total Assets 91.463 97.008 102.538 108.614 114.607
Property/Plant/Equipment, Total - Net 0.722 0.786 0.392 0.492 0.533
Other Long Term Assets, Total 0.041 0.04 0.039 0.042 0.041
Total Current Liabilities 2.801 4.523 4.072 3.856 4.438
Accounts Payable 0.697 1.934 0.768 1.242 2.315
Accrued Expenses 2.104 2.589 3.304 2.614 2.123
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 2.968 4.754 3.871 3.681 4.339
Total Long Term Debt 0 0 0 0 0
Minority Interest -0.254 -0.254 -0.254 -0.254 -0.254
Other Liabilities, Total 0.421 0.485 0.053 0.079 0.155
Total Equity 88.495 92.254 98.667 104.933 110.268
Common Stock 0.061 0.06 0.06 0.06 0.06
Additional Paid-In Capital 546.58 545.988 545.601 544.893 544.601
Retained Earnings (Accumulated Deficit) -457.242 -453.016 -446.222 -439.295 -433.613
Treasury Stock - Common -0.708 -0.708 -0.708 -0.708 -0.708
Other Equity, Total -0.196 -0.07 -0.064 -0.017 -0.072
Total Liabilities & Shareholders’ Equity 91.463 97.008 102.538 108.614 114.607
Total Common Shares Outstanding 60.5331 59.7897 59.7799 59.5175 59.499
Total Preferred Shares Outstanding 0.01 0.01 0.01 0.01 0.01
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -27.466 -8.141 -19.352 -16.168 22.2281
Cash From Operating Activities -22.245 -8.823 -18.882 -19.986 -20.8759
Cash From Operating Activities 0.055 0.063 0.065 0.225 0.372
Deferred Taxes 0 -12.1016
Non-Cash Items 4.519 1.572 1.527 1.306 -36.5223
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0 0 0 0.005 0.7119
Changes in Working Capital 0.647 -2.317 -1.122 -5.349 5.14797
Cash From Investing Activities -54.896 -7.277 21.432 -4.707 41.2706
Capital Expenditures -0.06 -0.02 0 -0.134 -0.13528
Other Investing Cash Flow Items, Total -54.836 -7.257 21.432 -4.573 41.4059
Cash From Financing Activities 85.276 18.58 1.183 0.824 -0.93177
Financing Cash Flow Items -0.248 -0.148 -0.13 -0.403 -0.4319
Issuance (Retirement) of Stock, Net 85.524 18.728 1.313 1.386 5.71526
Issuance (Retirement) of Debt, Net 0 -0.159 -6.21513
Net Change in Cash 8.135 2.48 3.733 -23.869 19.463
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -4.226 -27.466 -20.672 -13.745 -8.063
Cash From Operating Activities -5.642 -22.245 -17.641 -12.602 -7.975
Cash From Operating Activities 0.007 0.055 0.047 0.033 0.016
Non-Cash Items 1.275 4.519 3.564 2 0.92
Changes in Working Capital -2.698 0.647 -0.58 -0.89 -0.848
Cash From Investing Activities -6.09 -54.896 -71.354 -76.294 -65.09
Capital Expenditures -0.06 -0.06 -0.06 0
Other Investing Cash Flow Items, Total -6.09 -54.836 -71.294 -76.234 -65.09
Cash From Financing Activities -0.168 85.276 85.255 85.319 85.297
Financing Cash Flow Items -0.168 -0.248 -0.248 -0.184 -0.184
Issuance (Retirement) of Stock, Net 0 85.524 85.503 85.503 85.481
Net Change in Cash -11.9 8.135 -3.74 -3.577 12.232

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Lisata Therapeutics, Inc Company profile

About Caladrius Biosciences Inc

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).

Financial summary

BRIEF: For the 39 weeks ended 30 September 2021, Caladrius Biosciences Inc revenues was not reported. Net loss increased from $2.7M to $20.7M. Higher net loss reflects Research and development increase from $6.1M to $12.9M (expense), Other Selling, gen & admi increase of 18% to $7.7M (expense), Stock-based Compensation in R&D increase from $239K to $643K (expense).

Equity composition

Common Stock $.001 Par, 03/11, 500M auth., 78,564,199 issd. reverse acquisition with Fidelity Medical Services Inc. 08/06, Name changed from Phase III Medical, Inc. 08/07, Exchange changed from OTC to AMEX. 08/07, 1-for-10 reverse stock consolidation. Pref Stock B $0.1 Par, 10,000 issd., 07/13, 1-for-10 reverse sotck split.

Industry: Biotechnology & Medical Research (NEC)

110 Allen Road
Second Floor
07920

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

BTC/USD

44,252.10 Price
+2.010% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

71.41 Price
+2.320% 1D Chg, %
Long position overnight fee -0.0204%
Short position overnight fee -0.0015%
Overnight fee time 22:00 (UTC)
Spread 0.030

XRP/USD

0.68 Price
+4.560% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

US100

16,080.90 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading